NO310033B1 - Rekombinante virusvektorer kodende for hele eller en del av humane papillomavirus proteiner og anvendelsen derav - Google Patents

Rekombinante virusvektorer kodende for hele eller en del av humane papillomavirus proteiner og anvendelsen derav Download PDF

Info

Publication number: NO310033B1
Authority: NO; Norway
Prior art keywords: open reading; sequences; vector according; virus vector; nucleotide sequences
Prior art date: 1991-03-14

Application number

NO933260A

Other languages

English (en)

Norwegian (no)

Other versions

NO933260D0 (no

NO933260L (no

Inventor

Michael Edward Griff Boursnell

Stephen Charles Inglis

Alan James Munro

Original Assignee

Cantab Pharmaceuticals Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-14

Filing date

1993-09-13

Publication date

2001-05-07

1993-09-13 Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd

1993-09-13 Publication of NO933260D0 publication Critical patent/NO933260D0/no

1993-10-22 Publication of NO933260L publication Critical patent/NO933260L/no

2001-05-07 Publication of NO310033B1 publication Critical patent/NO310033B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 144
241000700605 Viruses Species 0.000 title claims abstract description 130
102000004169 proteins and genes Human genes 0.000 title claims abstract description 79
239000013598 vector Substances 0.000 title claims abstract description 59
241000701806 Human papillomavirus Species 0.000 title claims abstract description 57
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 59
230000006798 recombination Effects 0.000 claims abstract description 17
238000005215 recombination Methods 0.000 claims abstract description 17
229960005486 vaccine Drugs 0.000 claims abstract description 17
108010021466 Mutant Proteins Proteins 0.000 claims abstract description 14
102000008300 Mutant Proteins Human genes 0.000 claims abstract description 14
206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 10
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 10
201000010881 cervical cancer Diseases 0.000 claims abstract description 10
208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 8
101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 claims abstract description 5
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 5
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
229920001184 polypeptide Polymers 0.000 claims abstract description 4
108700026244 Open Reading Frames Proteins 0.000 claims description 59
241000700618 Vaccinia virus Species 0.000 claims description 58
241000341655 Human papillomavirus type 16 Species 0.000 claims description 44
230000007935 neutral effect Effects 0.000 claims description 44
210000004027 cell Anatomy 0.000 claims description 34
238000003780 insertion Methods 0.000 claims description 20
230000037431 insertion Effects 0.000 claims description 20
239000013603 viral vector Substances 0.000 claims description 17
239000002773 nucleotide Substances 0.000 claims description 16
125000003729 nucleotide group Chemical group 0.000 claims description 16
101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 claims description 15
239000002955 immunomodulating agent Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
108020004705 Codon Proteins 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
230000008859 change Effects 0.000 claims description 6
230000006378 damage Effects 0.000 claims description 6
230000003612 virological effect Effects 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 5
230000006870 function Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
230000004927 fusion Effects 0.000 claims description 4
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
230000003362 replicative effect Effects 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 abstract description 9
230000001024 immunotherapeutic effect Effects 0.000 abstract 2
235000018102 proteins Nutrition 0.000 description 60
108020004414 DNA Proteins 0.000 description 40
230000002068 genetic effect Effects 0.000 description 21
239000012634 fragment Substances 0.000 description 20
108700010070 Codon Usage Proteins 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 18
230000014509 gene expression Effects 0.000 description 18
239000013612 plasmid Substances 0.000 description 18
206010046865 Vaccinia virus infection Diseases 0.000 description 17
208000007089 vaccinia Diseases 0.000 description 17
101150013359 E7 gene Proteins 0.000 description 14
101100366942 Mus musculus Ston1 gene Proteins 0.000 description 13
238000010367 cloning Methods 0.000 description 13
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
238000011144 upstream manufacturing Methods 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
238000013519 translation Methods 0.000 description 9
230000014616 translation Effects 0.000 description 9
101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 8
238000002741 site-directed mutagenesis Methods 0.000 description 8
102000053602 DNA Human genes 0.000 description 7
108020005038 Terminator Codon Proteins 0.000 description 7
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
238000010276 construction Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
108020004202 Guanylate Kinase Proteins 0.000 description 5
101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
230000002246 oncogenic effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
208000024719 uterine cervix neoplasm Diseases 0.000 description 5
210000003501 vero cell Anatomy 0.000 description 5
108020005350 Initiator Codon Proteins 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
241001631646 Papillomaviridae Species 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
208000019065 cervical carcinoma Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
102000006638 guanylate kinase Human genes 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
231100000590 oncogenic Toxicity 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
108091029795 Intergenic region Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
241000700647 Variola virus Species 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
206010059313 Anogenital warts Diseases 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
101150071673 E6 gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101150109586 Gk gene Proteins 0.000 description 1
101000798109 Homo sapiens Melanotransferrin Proteins 0.000 description 1
101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
241000722343 Human papillomavirus types Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
101710132594 Protein E6 Proteins 0.000 description 1
101710132595 Protein E7 Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
206010038707 Respiratory papilloma Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000000531 effect on virus Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
102000049905 human MELTF Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000011293 immunotherapeutic strategy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000012966 insertion method Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000001018 virulence Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO933260A 1991-03-14 1993-09-13 Rekombinante virusvektorer kodende for hele eller en del av humane papillomavirus proteiner og anvendelsen derav NO310033B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919105383A GB9105383D0 (en)	1991-03-14	1991-03-14	An immunotherapeutic for cervical cancer
PCT/GB1992/000424 WO1992016636A1 (en)	1991-03-14	1992-03-10	Recombinant virus vectors encoding human papillomavirus proteins

Publications (3)

Publication Number	Publication Date
NO933260D0 NO933260D0 (no)	1993-09-13
NO933260L NO933260L (no)	1993-10-22
NO310033B1 true NO310033B1 (no)	2001-05-07

Family

ID=10691550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO933260A NO310033B1 (no)	1991-03-14	1993-09-13	Rekombinante virusvektorer kodende for hele eller en del av humane papillomavirus proteiner og anvendelsen derav

Country Status (17)

Country	Link
US (1)	US5719054A (da)
EP (1)	EP0576471B1 (da)
JP (1)	JPH06505626A (da)
KR (1)	KR100240183B1 (da)
CN (1)	CN1090239C (da)
AT (1)	ATE208824T1 (da)
AU (1)	AU665531B2 (da)
BR (1)	BR9205771A (da)
CA (1)	CA2106069A1 (da)
DE (1)	DE69232201T2 (da)
DK (1)	DK0576471T3 (da)
ES (1)	ES2168258T3 (da)
GB (1)	GB9105383D0 (da)
MX (1)	MX9205131A (da)
NO (1)	NO310033B1 (da)
OA (1)	OA10085A (da)
WO (1)	WO1992016636A1 (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993023570A1 (en) *	1992-05-11	1993-11-25	Pharmagenics, Inc.	Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US6153201A (en) *	1993-03-09	2000-11-28	University Of Rochester	Oral immunization with papillomavirus virus-like particles
US8062642B1 (en)	1993-03-09	2011-11-22	University Of Rochester	Production of papillomavirus capsid protein and virus-like particles
AT399656B (de) *	1993-03-19	1995-06-26	Boehringer Ingelheim Int	Verfahren zur herstellung von krebsvakzinen
US8791237B2 (en) *	1994-11-08	2014-07-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of non-hodgkins lymphoma
US8956621B2 (en) *	1994-11-08	2015-02-17	The Trustees Of The University Of Pennsylvania	Compositions and methods for treatment of cervical dysplasia
AUPN015794A0 (en)	1994-12-20	1995-01-19	Csl Limited	Variants of human papilloma virus antigens
AU4727296A (en) *	1995-02-24	1996-09-11	Cantab Pharmaceuticals Research Limited	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) *	1995-03-22	1995-05-10	Lynxvale Ltd	Anti-tumour treatment
US6165460A (en) *	1995-07-10	2000-12-26	Therion Biologics Corporation	Generation of immune responses to prostate-specific antigen (PSA)
AUPN443995A0 (en) *	1995-07-27	1995-08-17	Csl Limited	Papillomavirus polyprotein
HUP9904137A3 (en) *	1996-07-29	2001-06-28	Cantab Pharmaceuticals Res Ltd	Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US7118754B1 (en) *	1996-07-30	2006-10-10	Transgene S.A.	Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) *	1996-08-02	1998-02-05	Deutsches Krebsforsch	Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
ID19548A (id) *	1996-09-24	1998-07-23	Bavarian Nordic Res Inst As	Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
ES2245052T3 (es) *	1997-12-01	2005-12-16	Fang Fang	Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
CN101818145A (zh)	1998-03-20	2010-09-01	联邦科学和工业研究组织	控制基因表达
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
WO1999049891A1 (en) *	1998-03-30	1999-10-07	Thomas Jefferson University	Compositions and methods for providing a vpr-binding protein to a virion
DE19819476C1 (de) *	1998-04-30	2000-01-05	Deutsches Krebsforsch	Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
AU766403C (en) *	1998-09-04	2004-05-27	Aventis Pasteur Limited	Treatment of cervical cancer
US20030035798A1 (en) *	2000-08-16	2003-02-20	Fang Fang	Humanized antibodies
US6423885B1 (en)	1999-08-13	2002-07-23	Commonwealth Scientific And Industrial Research Organization (Csiro)	Methods for obtaining modified phenotypes in plant cells
EP2100620A1 (en) *	1999-09-16	2009-09-16	Eisai Corporation of North America	Nucleic acids encoding polyepitope polypeptides
US20050100928A1 (en) *	1999-09-16	2005-05-12	Zycos Inc., A Delaware Corporation	Nucleic acids encoding polyepitope polypeptides
AU2007201619B2 (en) *	1999-09-16	2011-05-12	Eisai Inc.	Nucleic acids encoding polyepitope polypeptides
CN102151337B (zh)	2000-03-13	2014-03-12	恩根尼公司	调节消化道蛋白表达的组合物和方法
AU2001249389A1 (en) *	2000-03-22	2001-10-03	The Children's Hospital Of Philadelphia	Modified blood clotting factors and methods of use
GB0105606D0 (en) *	2001-03-07	2001-04-25	Cantab Pharmaceuticals Res Ltd	Immunogens and vaccines and their preparation and use
WO2002072789A2 (en) *	2001-03-12	2002-09-19	Irm, Llc.	Genomics-driven high speed cellular assays, development thereof, and collections of cellular reporters
US20030170642A1 (en) *	2001-03-12	2003-09-11	Irm, Llc	Identification of cellular targets for biologically active molecules
WO2002077012A2 (en) *	2001-03-23	2002-10-03	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Human papilloma virus immunoreative peptides
US8771702B2 (en)	2001-03-26	2014-07-08	The Trustees Of The University Of Pennsylvania	Non-hemolytic LLO fusion proteins and methods of utilizing same
US20040091995A1 (en) *	2001-06-15	2004-05-13	Jeffrey Schlom	Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
AUPR621501A0 (en)	2001-07-06	2001-08-02	Commonwealth Scientific And Industrial Research Organisation	Delivery of ds rna
JP2005522192A (ja)	2001-07-19	2005-07-28	パーランセラピューティクス，インコーポレイテッド	マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
AU2002364124A1 (en) *	2001-11-28	2003-06-10	The Burnham Institute	Methods for identifying modulators of apoptosis
WO2004014314A2 (en) *	2002-08-12	2004-02-19	David Kirn	Methods and compositions concerning poxviruses and cancer
CA2499837C (en)	2002-10-03	2013-12-03	Wyeth Holdings Corporation	Human papillomavirus polypeptides and immunogenic compositions
AU2003284239B2 (en) *	2002-10-21	2008-08-21	Eisai Inc.	Compositions and methods for treating human papillomavirus-mediated disease
CA2516320C (en) *	2003-02-18	2015-05-26	Kevin Slawin	Induced activation in dendritic cells
ES2356154T3 (es)	2003-07-21	2011-04-05	Transgene S.A.	Citoquinas multifuncionales.
WO2005086967A2 (en) *	2004-03-11	2005-09-22	Shantha West, Inc.	Therapeutic use of rm1 antigen
EP1819732A2 (en)	2004-12-06	2007-08-22	Kirin Beer Kabushiki Kaisha	Human monoclonal antibodies to influenza m2 protein and methods of making and using same
EP2551282A3 (en)	2005-03-23	2013-02-13	Genmab A/S	Antibodies against CD38 for treatment of multiple myeloma
CN1308036C (zh) *	2005-03-28	2007-04-04	浙江大学医学院附属妇产科医院	一种hpv多肽疫苗及其制备方法
EP1933857A2 (en) *	2005-09-07	2008-06-25	Jennerex Biotherapeutics ULC	Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en)	2005-09-07	2015-03-17	Sillajen Biotherapeutics, Inc.	Oncolytic vaccinia virus cancer therapy
CA2524619A1 (en) *	2005-11-22	2007-05-22	Ottawa Health Research Institute	Novel stem cells, nucleotide sequences and proteins therefrom
TWI461436B (zh)	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2015785A4 (en) *	2006-04-24	2009-07-15	Shantha West Inc	AGRM2 ANTIGEN
US20100129403A1 (en) *	2006-06-20	2010-05-27	Transgene S.A.	Recombinant viral vaccine
EP2415783B1 (en)	2006-10-16	2016-12-14	Genelux Corporation	Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8691210B2 (en)	2006-10-19	2014-04-08	David M Spencer	Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
JP2010510772A (ja)	2006-11-27	2010-04-08	パトリスリミテッド	新生細胞における新規なグリコシル化ペプチド標的
CL2008000249A1 (es)	2007-01-30	2008-05-30	Transgene Sa	Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
KR20080084528A (ko) *	2007-03-15	2008-09-19	제네렉스 바이오테라퓨틱스 인크.	종양살상형 백시니아 바이러스 암 치료
KR101514473B1 (ko) *	2007-05-15	2015-04-22	트랜스진 에스.에이.	다중 유전자 발현용 벡터
US20090081639A1 (en) *	2007-05-31	2009-03-26	Phil Hill	Assay for sensitivity to chemotherapeutic agents
GB0710538D0 (en) *	2007-06-01	2007-07-11	Glaxo Group Ltd	Vaccine
WO2008156655A2 (en)	2007-06-15	2008-12-24	Genelux Corporation	Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) *	2007-07-18	2010-10-28	ジェネラックス・コーポレイション	腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
EP2185694A2 (en)	2007-08-02	2010-05-19	California Stem Cell, Inc.	Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
WO2009049350A1 (en) *	2007-10-15	2009-04-23	The University Of Queensland	Expression system for modulating an immune response
DK2212345T3 (da) *	2007-11-19	2016-03-21	Transgene Sa	Onkolytiske poxvirus-vektorer
US8466259B2 (en)	2007-12-07	2013-06-18	National Health Research Institutes	Adjuvants
TWI376385B (en)	2007-12-07	2012-11-11	Nat Health Research Institutes	Production of lipidated proteins in e. coli
AU2009292996B2 (en)	2008-09-22	2015-04-23	Baylor College Of Medicine	Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
US8211487B2 (en) *	2008-11-26	2012-07-03	Srinivasan Damodaran	Inhibition of ice crystal growth
US8647623B2 (en)	2009-04-10	2014-02-11	Kyowa Hakko Kirin Co., Ltd	Method for treatment of blood tumor using anti-TIM-3 antibody
ES2550639T3 (es)	2009-04-27	2015-11-11	Kyowa Hakko Kirin Co., Ltd.	Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
US8287880B2 (en)	2009-06-02	2012-10-16	National Health Research Institutes	Lipidated vaccine against dengue virus infection
US8658176B2 (en)	2009-06-22	2014-02-25	National Health Research Institutes	Lipidated tumor-associated antigens and immunotherapeutic compositions
KR101838472B1 (ko)	2009-09-14	2018-03-15	신라젠(주)	종양 용해 백시니아 바이러스 병용 암 치료요법
US9556272B2 (en)	2009-11-11	2017-01-31	The Trustees Of The University Of Pennsylvania	Anti-TEM1 antibodies and uses thereof
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
US9089520B2 (en)	2010-05-21	2015-07-28	Baylor College Of Medicine	Methods for inducing selective apoptosis
CA2799205A1 (en)	2010-05-25	2011-12-01	Qiagen Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
TWI507413B (zh) *	2010-11-15	2015-11-11	Nat Health Research Institutes	脂質化多抗原表位疫苗
TW201221642A (en)	2010-11-15	2012-06-01	Nat Health Research Institutes	Method of producing lipidated polypeptides
US9919047B2 (en)	2011-01-04	2018-03-20	Sillajen, Inc.	Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2697368B1 (en)	2011-04-15	2019-06-05	Genelux Corporation	Clonal strains of attenuated vaccinia viruses and methods of use thereof
US8951966B2 (en)	2011-07-01	2015-02-10	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP3533462A1 (en) *	2011-12-21	2019-09-04	Vaccibody AS	Vaccines against hpv
WO2013138522A2 (en)	2012-03-16	2013-09-19	Genelux Corporation	Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en)	2012-04-20	2013-10-24	Genelux Corporation	Imaging methods for oncolytic virus therapy
WO2013162748A1 (en)	2012-04-27	2013-10-31	The Trustees Of The University Of Pennsylvania	Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
CN102787134B (zh) *	2012-07-20	2014-11-05	西安交通大学	一种用于同源重组的自转运载体及其构建的经粘膜免疫疫苗
WO2014055960A1 (en)	2012-10-05	2014-04-10	Genelux Corporation	Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
JP6430949B2 (ja)	2012-10-23	2018-11-28	エモリーユニバーシティ	Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
KR20210090298A (ko)	2012-10-30	2021-07-19	에스퍼란스 파마슈티컬스, 인코포레이티드	항체/약물 컨쥬게이트 및 이의 사용 방법
EP3798228A1 (en)	2012-11-28	2021-03-31	NGM Biopharmaceuticals, Inc.	Compositions and methods for treatment of metabolic disorders and diseases
MX383664B (es)	2012-12-27	2025-03-14	Ngm Biopharmaceuticals Inc	Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
JP2016514091A (ja)	2013-02-08	2016-05-19	ミスフォールディングダイアグノスティクス，インコーポレイテッド	トランスサイレチン抗体およびその使用
US9434935B2 (en)	2013-03-10	2016-09-06	Bellicum Pharmaceuticals, Inc.	Modified caspase polypeptides and uses thereof
CA2905352A1 (en)	2013-03-14	2014-09-25	Bellicum Pharmaceuticals, Inc.	Methods for controlling t cell proliferation
EP3569253A1 (en)	2013-06-05	2019-11-20	Bellicum Pharmaceuticals, Inc.	Methods for inducing partial apoptosis using caspase polypeptides
WO2014210142A1 (en)	2013-06-25	2014-12-31	Temple University-Of The Commonwealth System Of Higher Education	Cortical bone-derived stem cells
WO2015103438A2 (en)	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103772508B (zh) *	2014-01-15	2017-05-10	深圳泰来生物医药有限公司	免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
EP3104866A4 (en)	2014-02-14	2017-08-02	Bellicum Pharmaceuticals, Inc.	Methods for activating t cells using an inducible chimeric polypeptide
AU2015312117A1 (en)	2014-09-02	2017-03-02	Bellicum Pharmaceuticals, Inc.	Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
SG11201702757YA (en)	2014-10-23	2017-05-30	Ngm Biopharmaceuticals Inc	Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016071758A1 (en)	2014-11-03	2016-05-12	Leiden University Medical Center	T cell receptors directed against bob1 and uses thereof
US10350245B2 (en)	2015-01-21	2019-07-16	Fred Hutchinson Cancer Research Center	Point-of-care and/or portable platform for gene therapy
US9901639B2 (en)	2015-02-13	2018-02-27	Temple University—Of the Commonwealth System of Higher Education	Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
AU2016230828B2 (en)	2015-03-10	2020-10-22	ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC)	T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
US10149887B2 (en)	2015-10-23	2018-12-11	Canbas Co., Ltd.	Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6728352B2 (ja)	2015-11-09	2020-07-22	エヌジーエムバイオファーマシューティカルス，インコーポレーテッド	胆汁酸に関係した障害の治療方法
CN108601951B (zh)	2015-12-09	2022-11-22	金港医疗(澳大利亚)私人有限公司	用于治疗的免疫调节组合物
JP2019505512A (ja)	2016-01-08	2019-02-28	バッシボディアクスイェセルスカプ	治療用抗癌ネオエピトープワクチン
CN109641037B (zh)	2016-04-13	2022-09-06	西安奥瑞单抗生物技术有限公司	抗psma抗体及其用途
US10512683B2 (en) *	2017-03-03	2019-12-24	Papivax Biotech Inc.	Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector
EP3621988A1 (en)	2017-05-09	2020-03-18	Bellicum Pharmaceuticals, Inc.	Methods to augment or alter signal transduction
CA3109871A1 (en)	2017-08-22	2019-02-28	Monash University	Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage)
CN119506283A (zh)	2017-09-15	2025-02-25	联邦科学技术研究组织	Rna分子
AU2018378955A1 (en)	2017-12-08	2020-06-18	Bellicum Pharmaceuticals, Inc.	Methods for enhancing and maintaining CAR-T cell efficacy
EP3849565A4 (en)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
WO2021205027A1 (en)	2020-04-09	2021-10-14	Vaccibody As	Individualized therapeutic anticancer vaccine
US20250199010A1 (en)	2020-12-31	2025-06-19	Alamar Biosciences, Inc.	Binder molecules with high affinity and/ or specificity and methods of making and use thereof
EP4551240A1 (en)	2022-07-08	2025-05-14	Viromissile, Inc.	Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
CN119464385B (zh) *	2024-12-04	2026-04-07	华中科技大学同济医学院附属同济医院	Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
FR2643817B1 (fr) *	1989-03-06	1993-12-17	Transgene Sa	Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0469089B1 (en) *	1989-04-18	1997-11-19	Applied Biotechnology, Inc.	Generation of hybrid genes and proteins by virus-mediated recombination

1991
- 1991-03-14 GB GB919105383A patent/GB9105383D0/en active Pending
1992
- 1992-03-10 KR KR1019930702746A patent/KR100240183B1/ko not_active Expired - Fee Related
- 1992-03-10 DK DK92906294T patent/DK0576471T3/da active
- 1992-03-10 DE DE69232201T patent/DE69232201T2/de not_active Expired - Fee Related
- 1992-03-10 BR BR9205771A patent/BR9205771A/pt not_active Application Discontinuation
- 1992-03-10 CA CA002106069A patent/CA2106069A1/en not_active Abandoned
- 1992-03-10 JP JP4505584A patent/JPH06505626A/ja not_active Withdrawn
- 1992-03-10 US US08/117,083 patent/US5719054A/en not_active Expired - Fee Related
- 1992-03-10 EP EP92906294A patent/EP0576471B1/en not_active Expired - Lifetime
- 1992-03-10 WO PCT/GB1992/000424 patent/WO1992016636A1/en not_active Ceased
- 1992-03-10 ES ES92906294T patent/ES2168258T3/es not_active Expired - Lifetime
- 1992-03-10 AU AU14147/92A patent/AU665531B2/en not_active Ceased
- 1992-03-10 AT AT92906294T patent/ATE208824T1/de not_active IP Right Cessation
- 1992-03-10 MX MX9205131A patent/MX9205131A/es not_active IP Right Cessation
- 1992-03-14 CN CN92101747A patent/CN1090239C/zh not_active Expired - Fee Related
1993
- 1993-09-13 NO NO933260A patent/NO310033B1/no not_active IP Right Cessation
- 1993-09-14 OA OA60411A patent/OA10085A/en unknown

Also Published As

Publication number	Publication date
DE69232201T2 (de)	2002-07-11
DE69232201D1 (de)	2001-12-20
NO933260D0 (no)	1993-09-13
KR100240183B1 (ko)	2000-01-15
NO933260L (no)	1993-10-22
GB9105383D0 (en)	1991-05-01
CN1064892A (zh)	1992-09-30
AU665531B2 (en)	1996-01-11
DK0576471T3 (da)	2002-03-11
ES2168258T3 (es)	2002-06-16
US5719054A (en)	1998-02-17
AU1414792A (en)	1992-10-21
BR9205771A (pt)	1994-06-07
EP0576471B1 (en)	2001-11-14
WO1992016636A1 (en)	1992-10-01
ATE208824T1 (de)	2001-11-15
EP0576471A1 (en)	1994-01-05
MX9205131A (es)	1994-06-30
OA10085A (en)	1996-12-18
JPH06505626A (ja)	1994-06-30
CA2106069A1 (en)	1992-09-15
CN1090239C (zh)	2002-09-04
HK1001657A1 (en)	1998-07-03

Legal Events

Date	Code	Title	Description
2004-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP0576471B1 (en)	2001-11-14	Recombinant virus vectors encoding human papillomavirus proteins
JP4489288B2 (ja)	2010-06-23	細胞における局在性が改変された免疫ポリペプチドに基づく抗腫瘍組成物
EP2367944B1 (en)	2019-01-09	Promoters for recombinant viral expression
CA2880060C (en)	2018-03-13	Chimpanzee adenovirus vaccine carriers
JP4198735B2 (ja)	2008-12-17	パピローマウイルス腫瘍および感染を治療するための医薬組成物
KR101196178B1 (ko)	2012-11-01	Ｈｉｖ 조절/부속 단백질의 융합 단백질
JP2011234731A (ja)	2011-11-24	ポックスウイルスゲノムへの異種遺伝子の組込みのためのベクター
WO1992005263A1 (en)	1992-04-02	Viral defective vaccine produced by transcomplementing cell line
US7118754B1 (en)	2006-10-10	Pharmaceutical composition for treating papillomavirus tumors and infection
Smith et al.	2024	The design, construction, and use of vaccinia virus recombinants
Gritz et al.	1990	Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env
US20050118139A1 (en)	2005-06-02	Vaccine using papilloma virus e proteins delivered by viral vector
HK1001657B (en)	2002-07-19	Recombinant virus vectors encoding human papillomavirus proteins
AU781653B2 (en)	2005-06-02	Pharmaceutical composition for treating papollomavirus tumour and infection
HK1177224A (en)	2013-08-16	Chimpanzee adenovirus vaccine carriers
WO2004108940A2 (en)	2004-12-16	Viral genome vectors
JPWO1998003635A1 (ja)	1999-08-24	アビポックスウイルスの増殖に非必須な領域、それを用いた組み換えアビポックスウイルス及びワクチン